11 news items
Analyst Ratings For Allogene Therapeutics
ALLO
31 May 24
0
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target
Piper Sandler Initiates Coverage On Allogene Therapeutics with Overweight Rating, Announces Price Target of $11
ALLO
31 May 24
Piper Sandler analyst Biren Amin initiates coverage on Allogene Therapeutics (NASDAQ:ALLO) with a Overweight rating and announces Price Target of $11.
Oppenheimer Maintains Outperform on Allogene Therapeutics, Lowers Price Target to $13
ALLO
21 May 24
Oppenheimer analyst Mark Breidenbach maintains Allogene Therapeutics (NASDAQ:ALLO) with a Outperform and lowers the price target from $14 to $13.
HC Wainwright & Co. Maintains Buy on Allogene Therapeutics, Lowers Price Target to $9
ALLO
16 May 24
HC Wainwright & Co. analyst Robert Burns maintains Allogene Therapeutics (NASDAQ:ALLO) with a Buy and lowers the price target from $10 to $9.
Breaking Down Allogene Therapeutics: 5 Analysts Share Their Views
ALLO
15 May 24
The 12-month price targets, analyzed by analysts, offer insights with an average target of $9.92, a high estimate
do498iue65tsfpsih0e81o4qw01rh8alro vm
ALLO
15 May 24
Truist Securities analyst Asthika Goonewardene maintains Allogene Therapeutics (NASDAQ:ALLO) with a Buy and maintains $17 price target.
vodi60q2ktn5t92c79cgy79ewj3wyd5fkqguoskhwxko6btsk8p4yc91eff
ALLO
14 May 24
Stifel analyst Benjamin Burnett maintains Allogene Therapeutics (NASDAQ:ALLO) with a Hold and raises the price target from $4.4 to $4.6.
8tx3 c9jp
ALLO
13 May 24
and the data readout of the primary EFS analysis in 2H 2026 with a Biologics License Application (BLA) submission targeted for 2027. Cema
4ulsecf9j6g9qbp14ryvhy0af9pxuttfdvcj6n96c77r8d
ALLO
26 Apr 24
the clinical development of ALLO-316, an AlloCAR T™ investigational product targeting CD70 in development for the treatment of advanced
a0rh2ktrfmk4tjt1huuujboaw3p80zcc86hgj1216ooftxu
ALLO
19 Mar 24
HC Wainwright & Co. analyst Robert Burns reiterates Allogene Therapeutics (NASDAQ:ALLO) with a Buy and maintains $10 price target.
sd2 tlutwypuc
ALLO
15 Mar 24
RBC Capital analyst Luca Issi reiterates Allogene Therapeutics (NASDAQ:ALLO) with a Outperform and maintains $10 price target.
- Prev
- 1
- Next